Table 2.
Analysis of clinical factors predisposing to achieve a Q8W dosing interval.
| Cox model | HR | 95% CI inf | 95% CI sup | p |
|---|---|---|---|---|
| Univariate analysis | ||||
| Age | 1.01 | 0.95 | 1.06 | 0.69 |
| Pseudophakic | 1.21 | 0.28 | 5.21 | 0.79 |
| Gender | 0.68 | 0.30 | 1.53 | 0.35 |
| Type 2 CNV | 2.24 | 1.07 | 4.68 | 0.03 |
| Type 3 CNV | 4.64 | 1.26 | 17.10 | 0.02 |
| VA at the time of diagnosis | 0.23 | 0.05 | 1.04 | 0.05 |
| ERM at the time of diagnosis | 0.99 | 0.99 | 1 | 0.61 |
| SRF height at the time of diagnosis | 0.99 | 0.99 | 1 | 0.36 |
| PED height at the time of diagnosis | 0.99 | 0.99 | 1 | 0.10 |
| IRF at the time of diagnosis | 1.55 | 0.73 | 3.29 | 0.24 |
| CNV surface area at the time of diagnosis | 0.97 | 0.90 | 1.04 | 0.46 |
| Atrophy area at the time of diagnosis | 1.11 | 1.02 | 1.21 | 0.01 |
| Vitrectomy | 1.32 | 0.4 | 4.37 | 0.64 |
| ERM | 1.48 | 0.70 | 3.09 | 0.29 |
| Macular hematoma | 0.9 | 0.27 | 2.97 | 0.86 |
| Multivariate analysis | ||||
| Type 2 CNV | 1.73 | 0.78 | 3.82 | 0.17 |
| Type 3 CNV | 4.55 | 1.22 | 16.89 | 0.02 |
| VA at the time of diagnosis | 0.33 | 0.06 | 1.71 | 0.18 |
| Atrophy area at the time of diagnosis | 1.09 | 1 | 1.20 | 0.04 |
Bold values are significant at p ≤ 0,05.